Home » Biotechnology » Immunohistochemistry Market

Immunohistochemistry Market By Product (Antibodies [Primary Antibodies, Secondary Antibodies], Equipment [Slide Staining System, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, Others], Reagents [Histological Stains, Blocking Sera and Reagent, Chromogenic Substrates, Fixation Reagents, Stabilizers, Organic Solvents, Proteolytic Enzymes, Diluents], Kits); By Application (Diagnostics [Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Nephrological Diseases], Research); By End-use (Hospitals & Diagnostic Laboratories, Research Institutes, Others); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Immunohistochemistry Market Size 2023	USD 3,102.96 million
Immunohistochemistry Market, CAGR	4.80%
Immunohistochemistry Market Size 2032	USD 4,731.81 million

Market Overview

The Global Immunohistochemistry Market is projected to grow from USD 3,102.96 million in 2023 to USD 4,731.81 million by 2032, at a compound annual growth rate (CAGR) of 4.80%.

The Global Immunohistochemistry Market is primarily driven by the increasing prevalence of chronic diseases and the rising demand for personalized medicine. Technological advancements in diagnostic techniques and the growing awareness of early cancer detection further propel market growth. Additionally, the expansion of healthcare infrastructure in emerging economies presents significant opportunities for market expansion. These factors collectively enhance the adoption of immunohistochemistry techniques, fostering sustained market growth.

The Global Immunohistochemistry Market showcases significant geographical diversity, with North America leading in market share due to advanced healthcare infrastructure, high healthcare spending, and a strong focus on research and development. Europe follows closely, driven by increasing cancer prevalence and robust government support for healthcare innovations. Asia-Pacific is rapidly emerging as a key player due to rising medical standards and growing investments in healthcare systems. Prominent market leaders include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, and Danaher Corporation, which are pivotal in driving innovation and expanding the reach of immunohistochemistry solutions globally.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Drivers

Rising Prevalence of Chronic Diseases and Aging Population

The Global Immunohistochemistry Market is significantly driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Immunohistochemistry (IHC) is pivotal in diagnosing and staging these conditions, making it an essential tool in medical diagnostics. For instance, more than half (53.8%) of adults aged 18–34 years reported having at least one chronic condition, and nearly one quarter (22.3%) reported having more than one chronic condition. Additionally, the aging global population contributes to the rise in age-related diseases, further amplifying the demand for effective diagnostic solutions like IHC. This demographic shift ensures a steady demand for advanced diagnostic techniques to manage and treat age-associated health issues.

Favorable Reimbursement Scenario and Drug Discovery Applications

The expansion of the immunohistochemistry market is further supported by favorable reimbursement policies and government initiatives that ensure insurance coverage for IHC tests. For instance, United Healthcare posts both the highest and lowest reimbursement rates for this test at $1,020 and $0.04 respectively. Such financial backing makes IHC more affordable and widespread, particularly in developed markets. Additionally, IHC plays a vital role in the drug discovery and development process, particularly in biomarker identification and the assessment of drug efficacy. For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. This integration of IHC in pharmaceutical research drives its demand in the drug development sector, pushing the market forward.

Technological Advancements and Rising Healthcare Expenditure

Market growth is also fueled by continuous technological advancements in IHC, including automated staining systems and sophisticated image analysis tools. These innovations enhance the efficiency and accuracy of IHC tests, making them more accessible and reliable for clinical use. Moreover, there is a notable increase in healthcare expenditure globally, with more investments flowing into healthcare infrastructure and diagnostic facilities. This surge in funding is crucial for the adoption of advanced diagnostic methods, including IHC, across various health systems.

Emerging Markets and Expanding Applications

Emerging markets, especially in developing countries, present significant growth opportunities due to increasing healthcare spending and the adoption of advanced diagnostic technologies. The growing awareness about the benefits of early disease diagnosis through IHC also contributes to market growth, improving patient outcomes and healthcare efficiency. Furthermore, the application of IHC is expanding beyond oncology into fields such as neuroscience, infectious diseases, and toxicology, broadening the scope and utilization of IHC techniques in various medical disciplines.

Market Trends

Emerging Trends in Artificial Intelligence and Companion Diagnostics

Emerging trends such as the integration of Artificial Intelligence (AI) in IHC are set to revolutionize the field further. AI-powered image analysis promises to enhance diagnostic accuracy and operational efficiency, making IHC a more powerful tool in the clinical setting. For instance, a multi-cohort trained model outperforms conventional single-cohort models in interpreting unseen IHCs (Kappa score 0.578 vs. up to 0.509) and consistently shows superior performance across different positive staining cutoff values. Moreover, the development of companion diagnostics is gaining momentum, utilizing IHC to aid in drug selection and patient stratification for more effective treatment plans. These advancements are pivotal in improving diagnostic precision, expanding the market to new applications, facilitating drug development, and increasing accessibility to IHC technologies in developing regions.

Integration of Digital Pathology and Expansion in Personalized Medicine

The Immunohistochemistry (IHC) market is undergoing a transformation with the increasing integration of digital pathology, which significantly enhances the accuracy, efficiency, and collaborative capabilities of IHC processes. Digital image analysis and storage systems allow for more precise diagnostics and easier access to historical data, leading to better patient outcomes. Additionally, the focus on personalized medicine is elevating the role of IHC in identifying specific biomarkers for targeted therapies. As the medical community continues to shift towards tailored treatment approaches, the demand for IHC-based diagnostics is expected to surge, supporting the development of more personalized therapeutic strategies and improving the efficacy of medical interventions.

Market Challenges Analysis

Economic and Operational Challenges in Immunohistochemistry

The Immunohistochemistry (IHC) market faces significant economic and logistical challenges that hinder its broader adoption. The high costs associated with IHC procedures, including the expenses for reagents, sophisticated equipment, and the need for skilled personnel, pose a substantial barrier, particularly in regions with limited healthcare funding. For instance, in 2020, U.S. health care costs grew 9.7%, to $4.1 trillion, reaching about $12,530 per person. This financial burden is exacerbated by the complex and labor-intensive nature of IHC techniques, which require specialized training and expertise. Such complexity not only increases operational costs but also leads to variability in results, impacting the consistency and reliability of diagnostic outcomes. Additionally, the IHC market is tightly regulated, with stringent standards governing the development and approval of new IHC products. These regulatory requirements prolong the time-to-market for new innovations and escalate development costs, further straining the resources of IHC providers.

Standardization Issues and Supply Chain Vulnerabilities

Further complicating the landscape are the challenges of standardization and supply chain stability. Variability in IHC protocols and the use of different reagents across laboratories can affect the reproducibility of results, hindering effective clinical decision-making and data comparison. This lack of standardization undermines the clinical utility of IHC, despite its diagnostic potential. Moreover, the IHC market is navigating through a competitive environment intensified by the expiration of key antibody patents, leading to increased market entry of competitors and subsequent price reductions and profit margin pressures. Reimbursement for IHC tests also presents a challenge, as obtaining adequate coverage can be difficult in various healthcare systems, affecting the financial viability of IHC operations. Additionally, global supply chain disruptions have recently impacted the availability and cost of essential reagents and equipment, further complicating the delivery of reliable IHC services and straining market growth. These combined challenges require strategic responses to ensure the sustainable development of the IHC market.

Market Segmentation Analysis:

By Product:

The Global Immunohistochemistry Market is segmented based on products into antibodies, equipment, reagents, and kits. Antibodies are further classified into primary and secondary antibodies, which are pivotal for accurate target detection in tissue samples. The equipment segment includes slide staining systems, tissue microarrays, tissue processing systems, and slide scanners, each playing a critical role in automating and enhancing the efficiency of the IHC process. Reagents such as histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents, stabilizers, organic solvents, proteolytic enzymes, and diluents are essential for the preparation and processing of samples. Kits, comprising a combination of these components, are designed to streamline various IHC protocols, offering convenience and consistency in diagnostic practices.

By Application:

In terms of application, the market is divided into diagnostics and research. The diagnostics segment is further categorized into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases. This segment highlights the extensive use of IHC in identifying and diagnosing various diseases through the detection of specific antigens in tissue samples. The research segment underscores the application of IHC in scientific studies, facilitating the understanding and development of treatments for various conditions. These applications demonstrate the versatility and critical importance of IHC across different medical and scientific fields, driving its adoption in both clinical and research settings.

Segments:

Based on Product:

Antibodies
Primary Antibodies
Secondary Antibodies
Equipment
Slide Staining System
Tissue Microarrays
Tissue Processing Systems
Slide Scanners
Others
Reagents
Histological stains
Blocking Sera and Reagent
Chromogenic Substrates
Fixation Reagents
Stabilizers
Organic Solvents
Proteolytic Enzymes
Diluents
Kits

Based on Application

Diagnostics
Cancer
Infectious Diseases
Cardiovascular Diseases
Autoimmune Diseases
Diabetes Mellitus
Nephrological Diseases
Research

Based on End-use:

Hospitals & Diagnostic Laboratories
Research Institutes
Others

Based on the Geography:

North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Regional Analysis

North America

North America dominates the global immunohistochemistry market, commanding a substantial 40% market share. This leadership position stems from a combination of factors that create a fertile environment for market growth. The region boasts highly advanced healthcare systems, characterized by state-of-the-art facilities, well-trained medical professionals, and a strong emphasis on preventive care and early diagnosis. For instance, a study involving 219 immunohistochemistry-requested and 80 control images demonstrated that an AI tool for automated immunohistochemistry requests could create a significantly leaner workflow and result in pathologist time savings, with an estimated 11 minutes saved on average per case. These systems readily embrace cutting-edge technologies, driving rapid adoption of innovative immunohistochemistry techniques and equipment. Furthermore, North America benefits from significant funding allocated to cancer research, both from government sources and private institutions. This financial support fuels continuous advancements in the field, leading to the development of more precise and efficient immunohistochemistry methods. The United States stands out as the powerhouse within the North American market, leveraging its robust pharmaceutical and biotechnology sectors to drive innovation and commercialization of immunohistochemistry products.

Europe

Europe follows closely behind North America, capturing approximately 35% of the global immunohistochemistry market share. The region’s strong performance is largely attributed to increasing government initiatives aimed at supporting cancer diagnosis and treatment. These initiatives often include funding for research, implementation of screening programs, and efforts to improve access to advanced diagnostic technologies like immunohistochemistry. Within Europe, countries such as Germany, the United Kingdom, and France are at the forefront of immunohistochemistry advancements. These nations possess world-class research institutions, a highly skilled workforce, and a strong tradition of medical innovation. Their healthcare systems prioritize early cancer detection and personalized treatment approaches, creating a robust demand for immunohistochemistry products and services.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Thermo Fisher Scientific Inc.
Hoffmann-La Roche Ltd.
Merck KGaA
Danaher Corporation
PerkinElmer, Inc.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Bio SB
Agilent Technologies, Inc.
Abcam plc.

Competitive Analysis

The competitive landscape of the Global Immunohistochemistry Market is characterized by the presence of major players like Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, and Danaher Corporation. Thermo Fisher Scientific leads with a robust product portfolio and extensive R&D investments, enhancing its market presence. F. Hoffmann-La Roche is renowned for its innovative diagnostic solutions and strong global distribution networks, securing a significant market share. Merck KGaA focuses on continuous innovation and strategic partnerships to bolster its market position, particularly in emerging markets. Danaher, through its subsidiaries, emphasizes on technological advancements and integration, aiming to offer comprehensive diagnostic solutions. These companies drive market competitiveness through innovation, strategic mergers and acquisitions, and expanding their geographic and product reach, ensuring they remain at the forefront of the immunohistochemistry industry.

Recent Developments

In January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market.
In May 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA -mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer.

Market Concentration & Characteristics

The Global Immunohistochemistry Market exhibits a moderate to high level of market concentration, with a few key players dominating the industry. These leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, and Danaher Corporation, significantly influence market dynamics through their extensive product portfolios, robust research and development capabilities, and expansive global distribution networks. This concentration enhances their ability to set market trends and negotiate favorable terms across supply chains. Furthermore, the market is characterized by high entry barriers due to the need for substantial investments in technology and compliance with stringent regulatory standards. These factors contribute to the competitive intensity and stability of the market, with major players continuously innovating and expanding their offerings to consolidate their market positions and respond to evolving healthcare demands.

Report Coverage

The research report offers an in-depth analysis based on Product, Application, End-use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Increased integration of digital pathology will continue to enhance the accuracy and efficiency of IHC diagnostics.
Growing prevalence of chronic diseases will drive sustained demand for IHC applications in disease diagnosis and management.
Expansion into emerging markets will accelerate as healthcare infrastructure improves and access to medical technology increases.
Technological advancements in automated IHC systems and image analysis will further streamline workflows and reduce turnaround times.
Personalized medicine trends will escalate the need for IHC in biomarker discovery and targeted therapy applications.
Greater focus on companion diagnostics will foster collaborations between pharmaceutical companies and diagnostic manufacturers.
Regulatory environments will evolve to keep pace with technological innovations, affecting product development and approval timelines.
Adoption of artificial intelligence and machine learning will improve the precision and interpretative capabilities of IHC.
Continued research and development efforts will lead to the introduction of novel reagents and antibodies, expanding the capabilities of IHC.
Strategic partnerships and acquisitions will shape the competitive landscape, as companies seek to enhance their product offerings and market reach.

CHAPTER NO. 1 : INTRODUCTION 20

1.1.1. Report Description 20

Purpose of the Report 20

USP & Key Offerings 20

1.1.2. Key Benefits for Stakeholders 20

1.1.3. Target Audience 21

1.1.4. Report Scope 21

CHAPTER NO. 2 : EXECUTIVE SUMMARY 22

2.1. Immunohistochemistry Market Snapshot 22

2.1.1. Global Immunohistochemistry Market, 2018 – 2032 (USD Million) 24

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 25

3.1. Russia-Ukraine and Israel-Palestine War Impacts 25

CHAPTER NO. 4 : IMMUNOHISTOCHEMISTRY MARKET – INDUSTRY ANALYSIS 26

4.1. Introduction 26

4.2. Market Drivers 27

4.2.1. Driving Factor 1 Analysis 27

4.2.2. Driving Factor 2 Analysis 28

4.3. Market Restraints 29

4.3.1. Restraining Factor Analysis 29

4.4. Market Opportunities 30

4.4.1. Market Opportunity Analysis 30

4.5. Porter’s Five Forces Analysis 31

CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 32

5.1. Company Market Share Analysis – 2023 32

5.1.1. Global Immunohistochemistry Market: Company Market Share, by Volume, 2023 32

5.1.2. Global Immunohistochemistry Market: Company Market Share, by Revenue, 2023 33

5.1.3. Global Immunohistochemistry Market: Top 6 Company Market Share, by Revenue, 2023 33

5.1.4. Global Immunohistochemistry Market: Top 3 Company Market Share, by Revenue, 2023 34

5.2. Global Immunohistochemistry Market Company Revenue Market Share, 2023 35

5.3. Company Assessment Metrics, 2023 36

5.3.1. Stars 36

5.3.2. Emerging Leaders 36

5.3.3. Pervasive Players 36

5.3.4. Participants 36

5.4. Start-ups /SMEs Assessment Metrics, 2023 36

5.4.1. Progressive Companies 36

5.4.2. Responsive Companies 36

5.4.3. Dynamic Companies 36

5.4.4. Starting Blocks 36

5.5. Strategic Developments 37

5.5.1. Acquisitions & Mergers 37

New Product Launch 37

Global Expansion 37

5.6. Key Players Product Matrix 38

CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 39

6.1. PESTEL 39

6.1.1. Political Factors 39

6.1.2. Economic Factors 39

6.1.3. Social Factors 39

6.1.4. Technological Factors 39

6.1.5. Environmental Factors 39

6.1.6. Legal Factors 39

6.2. Adjacent Market Analysis 39

CHAPTER NO. 7 : IMMUNOHISTOCHEMISTRY MARKET – BY PRODUCT SEGMENT ANALYSIS 40

7.1. Immunohistochemistry Market Overview, by Product Segment 40

7.1.1. Immunohistochemistry Market Revenue Share, By Product, 2023 & 2032 41

7.1.2. Immunohistochemistry Market Attractiveness Analysis, By Product 42

7.1.3. Incremental Revenue Growth Opportunity, by Product, 2024 – 2032 42

7.1.4. Immunohistochemistry Market Revenue, By Product, 2018, 2023, 2027 & 2032 43

7.2. Antibodies 44

7.2.1. Primary Antibodies 44

7.2.2. Secondary Antibodies 45

7.3. Equipment 46

7.3.1. Slide Staining System 46

7.3.2. Tissue Microarrays 47

7.3.3. Tissue Processing Systems 47

7.3.4. Slide Scanners 48

7.3.5. Others 48

7.4. Reagents 49

7.4.1. Histological stains 49

7.4.2. Blocking Sera and Reagent 50

7.4.3. Chromogenic Substrates 50

7.4.4. Fixation Reagents 51

7.4.5. Stabilizers 51

7.4.6. Organic Solvents 52

7.4.7. Proteolytic Enzymes 52

7.4.8. Diluents 53

7.5. Kits 53

CHAPTER NO. 8 : IMMUNOHISTOCHEMISTRY MARKET – BY APPLICATION SEGMENT ANALYSIS 54

8.1. Immunohistochemistry Market Overview, by Application Segment 54

8.1.1. Immunohistochemistry Market Revenue Share, By Application, 2023 & 2032 55

8.1.2. Immunohistochemistry Market Attractiveness Analysis, By Application 56

8.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 56

8.1.4. Immunohistochemistry Market Revenue, By Application, 2018, 2023, 2027 & 2032 57

8.2. Diagnostics 58

8.2.1. Cancer 58

8.2.2. Infectious Diseases 59

8.2.3. Cardiovascular Diseases 59

8.2.4. Autoimmune Diseases 60

8.2.5. Diabetes Mellitus 60

8.2.6. Nephrological Diseases 61

8.3. Research 61

CHAPTER NO. 9 : IMMUNOHISTOCHEMISTRY MARKET – BY END-USE SEGMENT ANALYSIS 62

9.1. Immunohistochemistry Market Overview, by End-use Segment 62

9.1.1. Immunohistochemistry Market Revenue Share, By End-use, 2023 & 2032 63

9.1.2. Immunohistochemistry Market Attractiveness Analysis, By End-use 64

9.1.3. Incremental Revenue Growth Opportunity, by End-use, 2024 – 2032 64

9.1.4. Immunohistochemistry Market Revenue, By End-use, 2018, 2023, 2027 & 2032 65

9.2. Hospitals & Diagnostic Laboratories 66

9.3. Research Institutes 67

9.4. Others 68

CHAPTER NO. 10 : IMMUNOHISTOCHEMISTRY MARKET – GLOBAL ANALYSIS 69

10.1. Product 69

10.1.1. Global Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 69

10.1.2. Global Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 69

10.2. Application 70

10.2.1. Global Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 70

10.2.2. Global Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 70

10.3. End-use 71

10.3.1. Global Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 71

10.3.2. Global Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 71

CHAPTER NO. 11 : IMMUNOHISTOCHEMISTRY MARKET – NORTH AMERICA 72

11.1. North America 72

11.1.1. Key Highlights 72

11.1.2. North America Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 73

11.1.3. North America Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 74

11.1.4. North America Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 75

11.1.5. North America Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 76

11.2. U.S. 77

11.3. Canada 77

11.4. Mexico 77

CHAPTER NO. 12 : IMMUNOHISTOCHEMISTRY MARKET – EUROPE 78

12.1. Europe 78

12.1.1. Key Highlights 78

12.1.2. Europe Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 79

12.1.3. Europe Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 80

12.1.4. Europe Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 81

12.1.5. Europe Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 82

12.2. UK 83

12.3. France 83

12.4. Germany 83

12.5. Italy 83

12.6. Spain 83

12.7. Russia 83

12.8. Belgium 83

12.9. Netherland 83

12.10. Austria 83

12.11. Sweden 83

12.12. Poland 83

12.13. Denmark 83

12.14. Switzerland 83

12.15. Rest of Europe 83

CHAPTER NO. 13 : IMMUNOHISTOCHEMISTRY MARKET – ASIA PACIFIC 84

13.1. Asia Pacific 84

13.1.1. Key Highlights 84

13.1.2. Asia Pacific Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 85

13.1.3. Asia Pacific Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 86

13.1.4. Asia Pacific Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 87

13.1.5. Asia Pacific Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 88

13.2. China 89

13.3. Japan 89

13.4. South Korea 89

13.5. India 89

13.6. Australia 89

13.7. Thailand 89

13.8. Indonesia 89

13.9. Vietnam 89

13.10. Malaysia 89

13.11. Philippines 89

13.12. Taiwan 89

13.13. Rest of Asia Pacific 89

CHAPTER NO. 14 : IMMUNOHISTOCHEMISTRY MARKET – LATIN AMERICA 90

14.1. Latin America 90

14.1.1. Key Highlights 90

14.1.2. Latin America Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 91

14.1.3. Latin America Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 92

14.1.4. Latin America Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 93

14.1.5. Latin America Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 94

14.2. Brazil 95

14.3. Argentina 95

14.4. Peru 95

14.5. Chile 95

14.6. Colombia 95

14.7. Rest of Latin America 95

CHAPTER NO. 15 : IMMUNOHISTOCHEMISTRY MARKET – MIDDLE EAST 96

15.1. Middle East 96

15.1.1. Key Highlights 96

15.1.2. Middle East Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 97

15.1.3. Middle East Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 98

15.1.4. Middle East Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 99

15.1.5. Middle East Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 100

15.2. UAE 101

15.3. KSA 101

15.4. Israel 101

15.5. Turkey 101

15.6. Iran 101

15.7. Rest of Middle East 101

CHAPTER NO. 16 : IMMUNOHISTOCHEMISTRY MARKET – AFRICA 102

16.1. Africa 102

16.1.1. Key Highlights 102

16.1.2. Africa Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 103

16.1.3. Africa Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 104

16.1.4. Africa Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 105

16.1.5. Africa Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 106

16.2. Egypt 107

16.3. Nigeria 107

16.4. Algeria 107

16.5. Morocco 107

16.6. Rest of Africa 107

CHAPTER NO. 17 : COMPANY PROFILES 108

17.1. Thermo Fisher Scientific Inc. 108

17.1.1. Company Overview 108

17.1.2. Product Portfolio 108

17.1.3. Swot Analysis 108

17.1.4. Business Strategy 109

17.1.5. Financial Overview 109

17.2. F. Hoffmann-La Roche Ltd. 110

17.3. Merck KGaA 110

17.4. Danaher Corporation 110

17.5. Perkinelmer, Inc. 110

17.6. Bio-Rad Laboratories, Inc. 110

17.7. Cell Signaling Technology, Inc. 110

17.8. Bio SB 110

17.9. Agilent Technologies, Inc. 110

17.10. Abcam plc. 110

CHAPTER NO. 18 : RESEARCH METHODOLOGY 111

18.1. Research Methodology 111

18.1.1. Phase I – Secondary Research 112

18.1.2. Phase II – Data Modeling 112

Company Share Analysis Model 113

Revenue Based Modeling 113

18.1.3. Phase III – Primary Research 114

18.1.4. Research Limitations 115

Assumptions 115

List of Figures

FIG NO. 1. Global Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 24

FIG NO. 2. Porter’s Five Forces Analysis for Global Immunohistochemistry Market 31

FIG NO. 3. Company Share Analysis, 2023 32

FIG NO. 4. Company Share Analysis, 2023 33

FIG NO. 5. Company Share Analysis, 2023 33

FIG NO. 6. Company Share Analysis, 2023 34

FIG NO. 7. Immunohistochemistry Market – Company Revenue Market Share, 2023 35

FIG NO. 8. Immunohistochemistry Market Revenue Share, By Product, 2023 & 2032 41

FIG NO. 9. Market Attractiveness Analysis, By Product 42

FIG NO. 10. Incremental Revenue Growth Opportunity by Product, 2024 – 2032 42

FIG NO. 11. Immunohistochemistry Market Revenue, By Product, 2018, 2023, 2027 & 2032 43

FIG NO. 12. Global Immunohistochemistry Market for Antibodies, Revenue (USD Million) 2018 – 2032 44

FIG NO. 13. Global Immunohistochemistry Market for Primary Antibodies, Revenue (USD Million) 2018 – 2032 44

FIG NO. 14. Global Immunohistochemistry Market for Secondary Antibodies, Revenue (USD Million) 2018 – 2032 45

FIG NO. 15. Global Immunohistochemistry Market for Equipment, Revenue (USD Million) 2018 – 2032 46

FIG NO. 16. Global Immunohistochemistry Market for Slide Staining System, Revenue (USD Million) 2018 – 2032 46

FIG NO. 17. Global Immunohistochemistry Market for Tissue Microarrays, Revenue (USD Million) 2018 – 2032 47

FIG NO. 18. Global Immunohistochemistry Market for Tissue Processing Systems, Revenue (USD Million) 2018 – 2032 47

FIG NO. 19. Global Immunohistochemistry Market for Slide Scanners, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Global Immunohistochemistry Market for Others, Revenue (USD Million) 2018 – 2032 48

FIG NO. 21. Global Immunohistochemistry Market for Reagents, Revenue (USD Million) 2018 – 2032 49

FIG NO. 22. Global Immunohistochemistry Market for Histological stains, Revenue (USD Million) 2018 – 2032 49

FIG NO. 23. Global Immunohistochemistry Market for Blocking Sera and Reagent, Revenue (USD Million) 2018 – 2032 50

FIG NO. 24. Global Immunohistochemistry Market for Chromogenic Substrates, Revenue (USD Million) 2018 – 2032 50

FIG NO. 25. Global Immunohistochemistry Market for Fixation Reagents, Revenue (USD Million) 2018 – 2032 51

FIG NO. 26. Global Immunohistochemistry Market for Stabilizers, Revenue (USD Million) 2018 – 2032 51

FIG NO. 27. Global Immunohistochemistry Market for Organic Solvents, Revenue (USD Million) 2018 – 2032 52

FIG NO. 28. Global Immunohistochemistry Market for Proteolytic Enzymes, Revenue (USD Million) 2018 – 2032 52

FIG NO. 29. Global Immunohistochemistry Market for Diluents, Revenue (USD Million) 2018 – 2032 53

FIG NO. 30. Global Immunohistochemistry Market for Kits, Revenue (USD Million) 2018 – 2032 53

FIG NO. 31. Immunohistochemistry Market Revenue Share, By Application, 2023 & 2032 55

FIG NO. 32. Market Attractiveness Analysis, By Application 56

FIG NO. 33. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 56

FIG NO. 34. Immunohistochemistry Market Revenue, By Application, 2018, 2023, 2027 & 2032 57

FIG NO. 35. Global Immunohistochemistry Market for Diagnostics, Revenue (USD Million) 2018 – 2032 58

FIG NO. 36. Global Immunohistochemistry Market for Cancer, Revenue (USD Million) 2018 – 2032 58

FIG NO. 37. Global Immunohistochemistry Market for Infectious Diseases, Revenue (USD Million) 2018 – 2032 59

FIG NO. 38. Global Immunohistochemistry Market for Cardiovascular Diseases, Revenue (USD Million) 2018 – 2032 59

FIG NO. 39. Global Immunohistochemistry Market for Autoimmune Diseases, Revenue (USD Million) 2018 – 2032 60

FIG NO. 40. Global Immunohistochemistry Market for Diabetes Mellitus, Revenue (USD Million) 2018 – 2032 60

FIG NO. 41. Global Immunohistochemistry Market for Nephrological Diseases, Revenue (USD Million) 2018 – 2032 61

FIG NO. 42. Global Immunohistochemistry Market for Research, Revenue (USD Million) 2018 – 2032 61

FIG NO. 43. Immunohistochemistry Market Revenue Share, By End-use, 2023 & 2032 63

FIG NO. 44. Market Attractiveness Analysis, By End-use 64

FIG NO. 45. Incremental Revenue Growth Opportunity by End-use, 2024 – 2032 64

FIG NO. 46. Immunohistochemistry Market Revenue, By End-use, 2018, 2023, 2027 & 2032 65

FIG NO. 47. Global Immunohistochemistry Market for Hospitals & Diagnostic Laboratories, Revenue (USD Million) 2018 – 2032 66

FIG NO. 48. Global Immunohistochemistry Market for Research Institutes, Revenue (USD Million) 2018 – 2032 67

FIG NO. 49. Global Immunohistochemistry Market for Others, Revenue (USD Million) 2018 – 2032 68

FIG NO. 50. North America Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 72

FIG NO. 51. Europe Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 78

FIG NO. 52. Asia Pacific Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 84

FIG NO. 53. Latin America Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 90

FIG NO. 54. Middle East Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 96

FIG NO. 55. Africa Immunohistochemistry Market Revenue, 2018 – 2032 (USD Million) 102

FIG NO. 56. Research Methodology – Detailed View 111

FIG NO. 57. Research Methodology 112

List of Tables

TABLE NO. 1. : Global Immunohistochemistry Market: Snapshot 22

TABLE NO. 2. : Drivers for the Immunohistochemistry Market: Impact Analysis 27

TABLE NO. 3. : Restraints for the Immunohistochemistry Market: Impact Analysis 29

TABLE NO. 4. : Global Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 69

TABLE NO. 5. : Global Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 69

TABLE NO. 6. : Global Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 70

TABLE NO. 7. : Global Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 70

TABLE NO. 8. : Global Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 71

TABLE NO. 9. : Global Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 71

TABLE NO. 10. : North America Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 73

TABLE NO. 11. : North America Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 73

TABLE NO. 12. : North America Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 74

TABLE NO. 13. : North America Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 74

TABLE NO. 14. : North America Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 75

TABLE NO. 15. : North America Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 75

TABLE NO. 16. : North America Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 76

TABLE NO. 17. : North America Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 76

TABLE NO. 18. : Europe Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 79

TABLE NO. 19. : Europe Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 79

TABLE NO. 20. : Europe Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 80

TABLE NO. 21. : Europe Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 80

TABLE NO. 22. : Europe Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 81

TABLE NO. 23. : Europe Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 81

TABLE NO. 24. : Europe Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 82

TABLE NO. 25. : Europe Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 82

TABLE NO. 26. : Asia Pacific Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 85

TABLE NO. 27. : Asia Pacific Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 85

TABLE NO. 28. : Asia Pacific Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 86

TABLE NO. 29. : Asia Pacific Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 86

TABLE NO. 30. : Asia Pacific Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 87

TABLE NO. 31. : Asia Pacific Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 87

TABLE NO. 32. : Asia Pacific Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 88

TABLE NO. 33. : Asia Pacific Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 88

TABLE NO. 34. : Latin America Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 91

TABLE NO. 35. : Latin America Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 91

TABLE NO. 36. : Latin America Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 92

TABLE NO. 37. : Latin America Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 92

TABLE NO. 38. : Latin America Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 93

TABLE NO. 39. : Latin America Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 93

TABLE NO. 40. : Latin America Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 94

TABLE NO. 41. : Latin America Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 94

TABLE NO. 42. : Middle East Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 97

TABLE NO. 43. : Middle East Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 97

TABLE NO. 44. : Middle East Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 98

TABLE NO. 45. : Middle East Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 98

TABLE NO. 46. : Middle East Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 99

TABLE NO. 47. : Middle East Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 99

TABLE NO. 48. : Middle East Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 100

TABLE NO. 49. : Middle East Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 100

TABLE NO. 50. : Africa Immunohistochemistry Market Revenue, By Country, 2018 – 2023 (USD Million) 103

TABLE NO. 51. : Africa Immunohistochemistry Market Revenue, By Country, 2024 – 2032 (USD Million) 103

TABLE NO. 52. : Africa Immunohistochemistry Market Revenue, By Product, 2018 – 2023 (USD Million) 104

TABLE NO. 53. : Africa Immunohistochemistry Market Revenue, By Product, 2024 – 2032 (USD Million) 104

TABLE NO. 54. : Africa Immunohistochemistry Market Revenue, By Application, 2018 – 2023 (USD Million) 105

TABLE NO. 55. : Africa Immunohistochemistry Market Revenue, By Application, 2024 – 2032 (USD Million) 105

TABLE NO. 56. : Africa Immunohistochemistry Market Revenue, By End-use, 2018 – 2023 (USD Million) 106

TABLE NO. 57. : Africa Immunohistochemistry Market Revenue, By End-use, 2024 – 2032 (USD Million) 106

Frequently Asked Question

What is the current size of the Global Immunohistochemistry Market?

As of 2023, the Global Immunohistochemistry Market is valued at USD 3,102.96 million.

What factors are driving the growth of the Global Immunohistochemistry Market?

The market is primarily driven by the increasing prevalence of chronic diseases, the rising demand for personalized medicine, advancements in diagnostic techniques, and the expansion of healthcare infrastructure in emerging economies.

What are the key segments within the Global Immunohistochemistry Market?

The key segments within the market include product types such as antibodies (primary and secondary), equipment (slide staining systems, tissue microarrays, etc.), reagents (histological stains, chromogenic substrates, etc.), and kits; and applications in diagnostics (cancer, infectious diseases, etc.) and research.

What are some challenges faced by the Global Immunohistochemistry Market?

Major challenges include the high cost of IHC procedures, complexity and labor-intensity of IHC techniques, stringent regulatory environments, lack of standardization, competition due to patent expiration, reimbursement issues, and supply chain disruptions.

Who are the major players in the Global Immunohistochemistry Market?

Key players in the market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation, and others, who lead in innovation and market expansion.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –